Objective. The SLE Responder Index (SRI) is a composite endpoint used in SLE trials. This investigation examined the clinical trial elements that drive response measured by the SRI.
Introduction
Clinical trials in SLE require efficacy endpoints that can assess benefit across multiple organ systems. Recently, several large trials have employed the SLE Responder Index (SRI) as a primary endpoint to assess efficacy [18] . SRI is a composite endpoint that measures clinical benefit across multiple organ systems while ensuring that benefit is not accompanied by deterioration in other organ systems [9] . Benefit is measured by the SLEDAI and must occur in the absence of clinical deterioration as measured by the BILAG or Physician's Global Assessment (PGA). Patients must also comply with concomitant medication rules and complete the trial to be considered an SRI responder.
The SRI has several useful characteristics, including the use of validated disease activity instruments, the ability to ensure improvement without deterioration and acceptance by regulatory authorities as a registration endpoint [10] .
A key limitation of the SRI is that the SLEDAI reflects only complete resolution of disease manifestations and not partial resolution, which could be clinically meaningful. In addition, it does not identify changes in specific disease manifestations.
To understand the impact of a therapy on specific disease manifestations, one has to examine the individual components of the disease activity instruments used for SRI. SLEDAI measures the presence or absence of specific disease manifestations due to lupus disease activity in nine organ systems. The SLEDAI score is the sum score from each organ system and, in general, more severe organ system manifestations have greater numerical value. Therefore, improvement in the SLEDAI does not distinguish between remission of a single severe disease manifestation and modest resolution of several milder disease manifestations. The BILAG is a complex instrument that measures 97 items in nine organ systems [11] . It can show some degree of incremental disease activity improvement and worsening but does not distinguish multiple disease manifestations within one organ system. The PGA is a visual analogue scale reflecting the physician's overall assessment of disease activity and does not distinguish between organ systems.
The data from previous phase 3 trials in SLE suggested that improvement in one disease activity instrument was rarely accompanied by worsening in another instrument [12] . Since this could have broad implications for trial designs, the current report examines data from two international phase 3 SLE trials that used SRI-5 as the primary endpoint [5, 6] to better understand the factors that drive SRI. Our hypothesis was that a better understanding of the SRI endpoint might provide insight for designing future SLE clinical trials.
Methods
The analyses are based on two large multinational phase 3 trials (n = 2262) that were designed to evaluate the impact of an anti-B-cell activating factor antibody on SLE disease activity using SRI-5 [5, 6] . All subjects provided written informed consent according to the Declaration of Helsinki and this study was approved by local ethical committees and institutional review boards. The current report makes no attempt to evaluate the efficacy of the therapeutic that was studied in the trials.
A detailed description of the methods for the clinical trials can be found in the primary publications. Protocols for the two trials were very similar. Briefly, trials 1 and 2 were 52-week double-blind, placebo-controlled studies with patients assigned 1:1:1 to placebo or one of two drug treatment arms. Increases or decreases in corticosteroid dose were allowed from screening through the first 24 weeks. Initiation or an increase in dose of antimalarials or immunosuppressants was not permitted. Key inclusion criteria included diagnosis of SLE according to ACR criteria, positive ANA titre 51:80 and a SLEDAI score 56. Patients with severe active lupus nephritis and/or CNS lupus were excluded, but stable, non-severe disease was allowed.
The primary endpoint for both studies was the proportion of patients achieving an SRI-5 response at week 52, defined as a 5 5 point improvement in the SELENA-SLEDAI score, no new BILAG 2004 score of A or no more than one new BILAG B score and no worsening (increase 50.3 points from baseline on a 3 point scale) in PGA. SRI-5 responders had to meet all three clinical criteria, comply with the concomitant medication rules and complete the trial. In trial 1, patients that decreased antimalarial or immunosuppressant treatment were also considered non-responders. As discussed in the original report [5] , it was recognized that imputation of non-response for decreasing background medications may have created a false-negative responder assignment.
The current analyses included all patients in the analysis of baseline disease characteristics. Analyses subsequent to randomization are confined to the placebo population, with the exception of the primary endpoint analysis, where the combined treatment groups provide additional information concerning the factors contributing to SRI-5 non-response. Analyses related to stability of the SRI-5 response over time were confined to weeks 24 and 52, as the primary endpoint was based on landmark analysis and corticosteroid dosing requirements were designed to be more stringent at these time points.
All other time course analyses were based on patients with the disease manifestation at baseline and at least one post-baseline assessment. These analyses were based on all observed data collected at each study visit. There were no assumptions made about missing data and analyses did not utilize data imputation for missing data. The extent of missing data at any time point is largely reflected in the early termination rates, which were comparable across treatment groups in both trials (supplementary Fig. S1 , available at Rheumatology Online). The reasons for early termination were also similar across treatment groups. Given the similar rates and reasons for early termination and the retrospective nature of several analyses, it was concluded that it would be more conservative to use observed data, and not imputed data, for the analyses.
Results
Trials 1 and 2 randomized 379 and 376 patients to placebo and 759 and 748 patients to the combined treatment arms, respectively.
SRI-5: reasons for non-response
Examination of the contribution of the three disease activity instruments (SLEDAI, BILAG, PGA) on SRI-5 response status confirms that improvement in the SLEDAI is a key driver of SRI response, while the disease activity instruments that measure deterioration have minimal incremental impact on the primary endpoint (Fig. 1) . Failure to achieve a 5 5 point reduction in the SLEDAI was observed in 29.6 and 35.1% of placebo patients and 30.7 and 30.1% of the combined treatment group in trials 1 and 2, respectively, after accounting for concomitant medication rules and premature discontinuation. In contrast, 0.6% (7/ 1138, trial 1) and 0.4% (4/1124, trial 2) of patients that completed the trials failed to achieve responder status due to deterioration by the BILAG or PGA after achieving a 5 5 point reduction in the SLEDAI and complying with concomitant medication rules.
Violation of concomitant medication rules and premature discontinuation had a substantial impact on SRI-5 rates. Non-response due to failure to comply with concomitant medication rules was observed in 19.8 and 17.0% of placebo patients and 16.7 and 14.3% of the combined treatment group in trials 1 and 2, respectively. Failure to complete the 52 week trial after complying with concomitant medications rules was observed in 20.1 and 20.2% of placebo patients and 18.8 and 18.4% of the combined treatment group in trials 1 and 2, respectively.
SRI-5: stability of response over time
Most of the improvement in SRI-5 was observed by 24 weeks, and this proportion remained relatively stable
FIG. 1 The SRI endpoint is driven by the SLEDAI, concomitant medication rules and trial completion
Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D). Reasons for non-response in panels B and D were determined sequentially in the order shown from left to right. The analyses are based on the intention-to-treat population, which included all patients that participated in a trial and received at least one dose of study drug. For trial 1, n = 379 in the placebo arm and n = 759 in the combined treatment arms. For trial 2, n = 376 in the placebo arm and n = 748 in the combined treatment arms. The combined treatment arms included an every 2 week and an every 4 week dose arm in each trial.
for the remainder of the trial. We examined the stability of the SRI-5 response between weeks 24 and 52 by evaluating the proportion of placebo-treated patients who changed response status between weeks 24 and 52. In the placebo arm, 17.4 and 13.2% of non-responders at week 24 achieved SRI-5 at week 52 in trials 1 and 2, respectively (supplementary Fig. S2 , available at Rheumatology Online). The proportion of placebo patients that deteriorated from week 24 (responder) to week 52 (non-responder) was 30.8 and 29.1% of week 24 responders in trials 1 and 2, respectively. Thus a substantial proportion of placebo patients changed response status between weeks 24 and 52.
Impact of high prevalence disease manifestations on SRI
The observation that the SLEDAI is the dominant disease activity instrument driving the SRI endpoint prompted further investigation into individual SLEDAI organ systems and disease manifestations. Three SLEDAI organ systems dominated baseline disease activity. Disease activity in mucocutaneous, musculoskeletal and immunologic organ systems was present in >70% of patients, while disease activity in the other six organ systems was present in <12% of patients ( Fig. 2A and C) .
We next examined the baseline prevalence of specific manifestations in the highly prevalent organ systems. Arthritis was the most common manifestation, present in 81 and 84.3% of patients in trials 1 and 2, respectively, while myositis was rare, present in only 1.2% of all patients. The mucocutaneous organ system is comprised of three manifestations: rash, alopecia and oral ulcers. The baseline prevalence of rash was 71 and 67.4%, alopecia was 61 and 55.4% and mucosal ulcer was 35.1 and 30% in trials 1 and 2, respectively (Fig 2B and D) .
These analyses revealed that the majority of clinical disease activity at baseline consisted of four SLE disease manifestations: arthritis, rash, alopecia and mucosal ulcers. In total, 98.6% (2231/2262) of patients had mucocutaneous and/or musculoskeletal organ system disease at baseline, while 95.9% (2170/2262) had rash and/or arthritis at baseline.
Response rates for the four prevalent disease manifestations (present at baseline, negative at follow-up visit) were analysed using the observed data (Fig. 3) . Mucosal ulcer had the highest response rate over time, while alopecia had the lowest response rate. Arthritis and rash
FIG. 2 Disease activity at baseline by the SLEDAI organ system and disease manifestation
Proportion of patients with active disease manifestations at baseline by the SLEDAI organ system (A and C) and specific SLEDAI disease manifestation (B and D) for the combined treatment populations in trial 1 (A and B) and trial 2 (C and D). Individual SLEDAI disease manifestations in panels B and D are shown for the three highly prevalent organ systems (mucocutaneous, musculoskeletal and immunologic) and are colour coded to their organ system in panels A and C. Percentages are calculated from the baseline values for the combined intention-to-treat population (placebo plus both dose arms) prior to first administration of the study drug (n = 1138 in trial 1 and n = 1124 in trial 2). response rates were intermediate between mucosal ulcer and alopecia. Week 52 placebo response rates for each specific disease manifestation were mucosal ulcers, 85.4 and 74.7%; rash, 47.8 and 54.3%; arthritis, 58.4 and 66.5%; and alopecia, 43.1 and 48.4% for trials 1 and 2, respectively.
Impact of low-prevalence disease manifestations on SRI Three of the six organ systems with low prevalence merited attention, as they have high point values in the SLEDAI. Vascular and CNS domains assign 8 points per disease manifestation, so remission of a single manifestation provides all the clinical benefit needed to achieve SRI-5. Vascular organ system disease was present in 7.6 and 7.2% of patients, while CNS organ system disease was present in 1.3 and 2% of patients in trials 1 and 2, respectively ( Fig. 4A and C) . CNS disease manifestations included visual disturbance (n = 12 and 20), lupus headache (n = 2 and 3) and organic brain syndrome (n = 1 and 0) in trials 1 and 2, respectively. The renal domain assigns 4 points per disease manifestation and was present in 10.4 and 9% of patients in trials 1 and 2, respectively. Renal disease manifestations included pyuria (n = 66 and 53), haematuria (n = 48 and 46), proteinuria (n = 39 and 35) and urinary casts (n = 1 and 6) in trials 1 and 2, respectively.
While the proportion of patients with renal, vascular or CNS organ system involvement at baseline was <11% for any single organ system, most of these patients (93.2 and 93.8% in trials 1 and 2, respectively) had only one of these three organ systems active at baseline. Thus the proportion of patients with high-value, low-prevalence organ systems active at baseline approximated the total number of patients with renal, vascular and CNS disease at baseline, with 18.1 and 17.2% of patients active in trials 1 and 2, respectively. The week 52 SRI-5 response rate for placebo patients with CNS, vascular or renal involvement at baseline ranged from 45 to 67% in the two trials ( Fig. 4B  and D) . The remaining three organ systems with low prevalence at baseline assign 12 points per manifestation and were not further evaluated.
Concomitant medications
Most patients were taking SLE-related medications at baseline, including corticosteroids (78.3 and 74.1%), immunosuppressants (43.8 and 39.9%) and antimalarials (63.7 and 70.3%) in trials 1 and 2, respectively. To better understand the impact of corticosteroids, we analysed the cumulative proportion of placebo patients with an increase in average daily prednisone dose of 52.5 mg/ day between visits. Less than 20% of placebo patients met this threshold for an increase in prednisone over the first 24 weeks (Fig. 5 ). Placebo patients with increased
FIG. 3 Response rates for high-prevalence SLEDAI disease manifestations in placebo patients
Response rate over time in the placebo population for the four high-prevalence SLEDAI clinical disease manifestations [(A) arthritis; (B) rash; (C) alopecia; (D) mucosal ulcer]. Each analysis represents the subpopulation of placebo patients that had the disease manifestation at baseline by the SLEDAI. Patients were considered responders if the disease manifestation had resolved at the indicated visit. At baseline, the analysis included arthritis (n = 306 and 313), rash (n = 270 and 245), alopecia (n = 235 and 209) and mucosal ulcer (n = 135 and 107) for trials 1 and 2, respectively. Analyses were conducted using observed data at each visit with no imputation for missing data or dropouts. corticosteroids were evident throughout the trials (supplementary Fig. S3 , available at Rheumatology Online).
Since increases in prednisone may reflect clinical deterioration, we evaluated the SRI-5 response in patients with increases in prednisone during the first 24 weeks. The SRI-5 response at week 24 in placebo patients with increased prednisone dose was 26.1 and 25% in trials 1 and 2, respectively (Fig. 6) .
Few patients discontinued corticosteroids during the trial [3.1% (9/294) and 2.2% (6/274) discontinued corticosteroids in trials 1 and 2, respectively]. Increases in immunosuppressants and antimalarials were also infrequent in the trials [4.5% (17/379) and 5.6% (21/376) increased immunosuppressants or antimalarials in trials 1 and 2, respectively].
Discussion
This study examined two large phase 3 SLE trials to evaluate factors that impact SRI response status in SLE trials. The analyses demonstrate that improvement in the SLEDAI, concomitant medication rules and early termination are the parameters that most strongly influence response status in SRI-5-based SLE trials. The BILAG and PGA are valuable instruments, but when used to counter response status in patients who have already met improvement criteria, they have negligible incremental impact on response status. Four clinical manifestations-rash, arthritis, alopecia and mucosal ulcer-are highly prevalent at baseline, while all other clinical manifestations are much less prevalent. These four clinical manifestations, along with anti-dsDNA and low complement, provide most of the opportunity for improvement in the SLEDAI.
The analyses showing that the BILAG and PGA contribute minimal additional incremental information to the SRI reflect the order in which the terms are analysed, not the individual value of the BILAG and PGA. The principle behind the SRI-improvement without worsening-influences the order of the calculations to determine responders and non-responders. The hierarchy logically begins with identifying those patients that could never achieve responder status due to failure to complete the trial or violation of the concomitant medication rules. Improvement in the SLEDAI is the next gate, followed by   FIG. 4 Impact of rare, highly weighted SLEDAI disease manifestations on the SRI endpoint Baseline prevalence of renal, vascular and CNS disease as measured by the SLEDAI organ system in the intention-to-treat (ITT) population (A and C) and SRI-5 response rate in placebo patients with renal, vascular and CNS disease at week 52 (B and D) in trial 1 (A and B) and trial 2 (C and D). Renal, vascular and CNS organ systems were investigated due to high SLEDAI point values when calculating SRI-5 response rates. Few patients had activity in more than one of these organ systems at baseline, as indicated in panels A and C. SRI-5 response rates in placebo patients with renal, vascular or CNS disease were greater than the response rate in the ITT populations. SRI-5 response rates are confined to placebo and based on ITT (n = 379 and 376), renal (n = 42 and 30), vascular (n = 30 and 26) and CNS (n = 6 and 7) in trials 1 and 2, respectively. the BILAG and PGA to identify patients with worsening disease despite improvement in the SLEDAI. This was a meaningful theoretical construct since the SLEDAI score does not increase when a sign or symptom that was present at baseline worsens. The current data confirm that improvement in the SLEDAI is rarely accompanied by deterioration in the BILAG or PGA.
Individually, the SLEDAI, BILAG and PGA all provide value, as they allow one to estimate the proportion of patients that improved and the proportion that worsened over the course of a trial. However, for clinical trials that are intended to study new therapeutics in SLE patients with common, non-major organ-threatening disease manifestations, a simple dichotomous improvement in the SLEDAI score, coupled with successful trial completion and medication stability, may provide a simple and potentially more clinically relevant approach to assess outcome. Clinical trials will continue to require an assessment of worsening/deterioration, including both safety and flare analyses. Evaluation of therapeutics for infrequent SLE disease manifestations will likely require trial designs that enrich for the population of interest.
The original derivation of the SRI by Furie et al. [9] has had a major impact on SLE drug development, having since been deployed as the primary endpoint in many clinical trials. Interestingly, there is an important difference in the definition of non-response between the original SRI and the SRI endpoint used in current trials. Because there was unlimited flexibility with background medications in the trial used to derive the SRI, the original SRI did not account for increases in concomitant medications. Thus the original SRI identified a number of patients with BILAG or PGA worsening, despite SLEDAI improvement. In its current iteration, the SRI captures many of these patients with worsening disease by the increase in therapies used to treat the disease activity.
The prevalence and response patterns of the four most common clinical manifestations illustrate how they impact the SRI. Arthritis and rash were the most prevalent manifestations, as >95% of patients had one or both of these manifestations. Placebo response rates for rash, arthritis and alopecia are in a range where an effective treatment has the potential to show benefit over and above standard therapy. In contrast, placebo response rates for mucosal ulcer were high, approaching 80% at 52 weeks. This high placebo rate for mucosal ulcer could potentially limit the ability to detect a treatment benefit for a drug that was effective for this manifestation. It is noted that these response rates would be lower when non-response is imputed for early termination and violation of concomitant medication rules.
The SLEDAI point value for arthritis, rash, alopecia and mucosal ulcers is not sufficient in isolation to qualify patients for trials that require a SLEDAI score 56 for enrolment. Thus these manifestations represent the most frequent manifestations in the larger constellation of disease activity present in the clinical trial population.
We examined the six SLEDAI organ systems with low prevalence at baseline to see how activity in those systems at baseline impacted the SRI response. Less than 11% of patients had disease activity in each of these organ systems at baseline, therefore analysis of response in these organ systems is likely to be underpowered for treatment benefit, even in large phase 3 trials. However, the low-prevalence organ systems with high point value in the SLEDAI are of interest, since remission in a single manifestation within these organ systems can provide most or all of the SLEDAI improvement needed to achieve an SRI response. There was little overlap between patients with CNS, vascular or renal disease activity at baseline. Thus, cumulatively they represented 1718% of the patients in the trial. Placebo patients with disease activity in these three organ systems at baseline had SRI-5 response rates that were greater than the intention-to-treat placebo SRI-5 response rate. Thus these high-value organ systems, which clearly reflect important and serious manifestations of SLE, have the potential to impact the trial outcome despite their relatively low prevalence at baseline.
The time course of the SRI response curve in these trials was similar to that observed in most recent 52 week SLE trials, where the change from baseline is greatest over the first 6 months, followed by a relatively stable proportion of responders in the second half of the trial [1, 2, 5, 6, 8] . It was interesting to observe that many placebo patients changed response status between weeks 24 and 52, from SRI responder to non-responder, and vice versa. While response at week 24 was maintained to week 52, response at earlier time points, that is, 6 months, may more accurately reflect improvement in baseline disease activity.
FIG. 5 Placebo patients that increased corticosteroids after randomization
Cumulative proportion of placebo patients with an increase in average daily prednisone use of 5 2.5 mg/day between visits during the first 24 weeks in trials 1 and 2. Analysis was limited to placebo patients during the first 24 weeks when increases in steroids were allowed. The number of patients at randomization was 379 and 376 in trials 1 and 2, respectively.
Many SLE trials have allowed increases in corticosteroids after randomization. Our analyses reveal that <20% of patients increased their average daily prednisone dose by > 2.5 mg/day between visits during the first 24 weeks, a period where the protocol permitted increases in prednisone. These data suggest it may be feasible to completely restrict increases in corticosteroid doses after randomization in an SLE population with non-organ-threatening disease manifestations. Patients with exacerbating disease activity could still receive rescue therapy, but they would be considered non-responders in the analysis.
Increases in corticosteroid doses may reflect clinical deterioration. Thus it was not surprising that SRI-5 response rates at week 24 were lower in patients receiving increases in corticosteroids compared with patients with stable prednisone doses. However, 25% of placebo patients receiving an increase in corticosteroid doses during the first 24 weeks did achieve an SRI-5 response at week 24, consistent with the possibility that increases in corticosteroid dose may have contributed to the SRI-5 response rate at week 24 in placebo patients that otherwise may not have achieved responder status due to clinical deterioration.
It is not possible to generalize the observations reported here to other SRI-driven SLE trials without repeating the specific analyses. However, there are data indicating that at least some of the observations are likely to be qualitatively similar across trials. For example, in the belimumab phase 3 SLE trials, the proportion of patients with a 5 4 point reduction in SLEDAI that failed to achieve an SRI-4 due to worsening of the BILAG or PGA ranged from 0.3 to 2.2% after accounting for dropouts and rescue medication [12] . An independent study also confirmed that the SLEDAI does not conceal worsening in other organ systems when there is overall improvement [13] . Disease involvement by organ system in the belimumab phase 3 trials was similar to the current observations, where mucocutaneous, musculoskeletal and immunological organ domains were the most prevalent SLEDAI organ domains at baseline and the other six organ domains were much less prevalent [14] . The concomitant medication analyses reported here are less readily generalized to other SRI-based trials, as the rules governing changes in concomitant medications, especially corticosteroids, are often unique to each trial.
In conclusion, the analyses identify the efficacy variables that have the greatest impact on SRI response status, as well as the variables that may confound assessment of treatment effect. The results show that the SLEDAI, concomitant medication rules and trial completion are the major drivers of SRI responder status. They also show that a relatively finite number of disease manifestations in the SLEDAI drive SRI outcomes. Finally, the analyses characterize variables that potentially contribute noise in the trial, including corticosteroids and rare, highly weighted disease manifestations within the SLEDAI.
FIG. 6
Impact of increases in corticosteroids on SRI endpoint in the placebo population SRI-5 response rate at week 24 in the subset of placebo patients that were taking corticosteroids at baseline in (A) trial 1 and (B) trial 2. Placebo patients were separated into two populations for the analysis: patients with stable corticosteroids that did not increase >2.5 mg/day between visits and patients that had protocol permitted increases in corticosteroids, defined as a 5 2.5 mg/day increase in average daily prednisone use between visits during the first 24 weeks. The number of patients in each analysis is defined as the number achieving SRI-5 at week 24/total number of patients in the subset.
